BioXcel Therapeutics Prepares to Initiate Pivotal Phase 3 Studies with BXCL501 Following Positive End-of-Phase 2 Meeting with FDA Dec 3, 2019
BioXcel Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update Nov 14, 2019
BioXcel Therapeutics to Host Third Quarter 2019 Operating and Financial Results Conference Call and Webcast Nov 7, 2019
BioXcel Therapeutics to Present at the 26th Annual Prostate Cancer Foundation Scientific Retreat Oct 24, 2019
BioXcel Therapeutics Announces BXCL501 Program Initiative for Prevention and Treatment of Acute Agitation using Wearable Digital Devices Sep 18, 2019
BioXcel Therapeutics Receives FDA Orphan Drug Designation for BXCL701 for the Treatment of Acute Myeloid Leukemia (AML) Sep 4, 2019
